FinanceCity
HealthcareNSE · BSE

Natco Pharma Ltd.

NATCOPHARM · ISIN INE987B01026

Share price

₹849 +0.21%

Market capitalisation

₹15214 CrClosed

Live from Yahoo Finance. Pulse animates during NSE market hours (9:15–15:30 IST, weekdays).

01 · Key metrics

Market cap

₹15214 Cr

Current price

₹849

+0.21% today

52W high

₹1,227

52W low

₹789

Stock P/E

10.73

P/B ratio

1.76

02 · Per share & returns

EPS (TTM)

₹79.17

Book value

₹483

ROE

16.85%

ROA

7.80%

Dividend yield

0.77%

Beta

0.19

03 · Financials (TTM)

By the numbers

Revenue

₹4078 Cr

-39.60% YoY

EBITDA

₹1436 Cr

Net profit

₹1419 Cr

-34.10% YoY

Profit margin

34.78%

Operating margin

10.44%

Total debt

₹714 Cr

Total cash

₹2129 Cr

Debt / equity

0.08x

Current ratio

3.01x

Payout ratio

6.31%

04 · Analyst view

Target price

₹1,021

Upside

+20.23%

Consensus

HOLD

Analysts

9

05 · Shareholding pattern

Who owns NATCOPHARM?

  • Promoters

    49.42%

    Founders & promoter group

  • Institutions

    12.20%

    FII + DII

  • Public

    38.38%

    Retail & non-institutional

As of 31 Mar 2026 · Source: NSE corporate filings

06 · Registration & listing

On the record

Symbol
NATCOPHARM
Exchange
NSE · BSE
CIN
ISIN
INE987B01026
BSE code
524816
Sector
Healthcare
Industry
Healthcare
Face value
₹2
Listing date
26 Dec 1995
Employees
Headquarters
Hyderabad, India

07 · About

What is Natco Pharma Ltd.?

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

08 · Common questions

Frequently asked

What is the CIN of Natco Pharma Ltd.?+

The Corporate Identity Number for Natco Pharma Ltd. is published in the MCA21 corporate master. FinanceCity backfills CIN values during weekly refreshes.

Who are the promoters of Natco Pharma Ltd.?+

Promoter holding in NATCOPHARM is approximately 49.42%, as disclosed in the latest published shareholding pattern.

What is the market capitalisation of Natco Pharma Ltd.?+

Natco Pharma Ltd. (NATCOPHARM) has a market capitalisation of approximately ₹15214 Cr, reflecting the most recent weekly refresh from the BSE scrip master.

09 · Adjacent

Other healthcare listings

Full sector →